COVID-19 and Blood Coagulation: Implications for Hemostasis

Abstract

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a global health crisis with multifaceted clinical manifestations. Apart from respiratory distress, increasing evidence highlights the intricate relationship between COVID-19 and blood coagulation, significantly impacting hemostasis mechanisms. This paper aims to elucidate the complex interplay between COVID-19 and blood coagulation, delineating the implications for hemostasis, thrombotic events, and their clinical repercussions.COVID-19 is recognized for its diverse clinical presentations, extending beyond respiratory involvement. A growing body of research underscores the association between COVID-19 and coagulopathy, revealing disturbances in various facets of blood coagulation. This review synthesizes current knowledge, exploring the underlying mechanisms of COVID-19-induced coagulopathy and its profound implications for hemostasis.Moreover, this paper delves into the impact of COVID-19 on fundamental hemostasis mechanisms, encompassing disruptions in clotting factors, platelet function, fibrinolysis, and endothelial integrity. A comprehensive understanding of these interactions is pivotal in shaping clinical management strategies and improving outcomes for individuals affected by COVID-19.

Full text

Int. J. Curr. Res. Med. Sci. (2023). 9(11): 16-22
16
International Journal of Current Research in
Medical Sciences
ISSN: 2454-5716
(A Peer Reviewed, Indexed and Open Access Journal)
www.ijcrims.com
Review Article Volume 9, Issue 11 -2023
COVID-19 and Blood Coagulation: Implications for
Hemostasis
*Emmanuel Ifeanyi Obeagu1, Getrude Uzoma Obeagu2and
Matthew Chibunna Igwe3
1Department of Medical Laboratory Science, Kampala International University, Uganda.
2School of Nursing Science,Kampala International University, Uganda.
3Department of Public Health, Kampala International University, Uganda.
*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science,
Kampala International University, Uganda.
E-mail: emmanuelobeagu@yahoo.com,obeagu.emmanuel@kiu.ac.ug,0000-0002-4538-0161
Abstract
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has emerged as a global health crisis with multifaceted clinical manifestations. Apart from respiratory distress,
increasing evidence highlights the intricate relationship between COVID-19 and blood coagulation, significantly
impacting hemostasis mechanisms. This paper aims to elucidate the complex interplay between COVID-19 and blood
coagulation, delineating the implications for hemostasis, thrombotic events, and their clinical repercussions.COVID-
19 is recognized for its diverse clinical presentations, extending beyond respiratory involvement. A growing body of
research underscores the association between COVID-19 and coagulopathy, revealing disturbances in various facets
of blood coagulation. This review synthesizes current knowledge, exploring the underlying mechanisms of COVID-
19-induced coagulopathy and its profound implications for hemostasis.Moreover, this paper delves into the impact of
COVID-19 on fundamental hemostasis mechanisms, encompassing disruptions in clotting factors, platelet function,
fibrinolysis, and endothelial integrity. A comprehensive understanding of these interactions is pivotal in shaping
clinical management strategies and improving outcomes for individuals affected by COVID-19.
Keywords: COVID-19, SARS-CoV-2, Blood Coagulation, Hemostasis, Thrombosis, Coagulopathy
DOI: http://dx.doi.org/10.22192/ijcrms.2023.09.11.003

Int. J. Curr. Res. Med. Sci. (2023). 9(11): 16-22
17
Introduction
The coronavirus disease 2019 (COVID-19)
pandemic caused by the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-
2) has sparked a global health crisis of
unprecedented proportions. While respiratory
complications have been the hallmark of this viral
illness, mounting evidence has underscored the
intricate connection between COVID-19 and
aberrant blood coagulation, presenting profound
implications for hemostasis and thrombotic events
[1-7].COVID-19 manifests with a spectrum of
clinical manifestations, extending beyond
respiratory distress to encompass systemic
complications affecting various organ systems. Of
notable concern is the increasing recognition of
coagulation abnormalities and thrombotic events
observed in a subset of COVID-19 patients. This
review seeks to unravel the intricate relationship
between COVID-19 and blood coagulation,
elucidating the underlying mechanisms and
highlighting the consequential implications for
hemostasis [8-11].
The convergence of COVID-19 with coagulation
abnormalities has raised pertinent questions
regarding the pathophysiological mechanisms
driving these phenomena. Emerging evidence
suggests multifaceted interactions, involving
endothelial dysfunction, dysregulated
inflammatory responses, heightened platelet
activation, and disruptions in the coagulation
cascade, contributing to a prothrombotic state in
severe COVID-19 cases.Moreover, this paper
aims to explore the impact of COVID-19 on
fundamental hemostatic mechanisms,
encompassing alterations in clotting factors,
platelet function, fibrinolysis, and endothelial
integrity. These perturbations in hemostasis not
only contribute to the thrombotic complications
observed in COVID-19 patients but also
potentially influence disease severity and clinical
outcomes.Understanding the implications of
COVID-19 on hemostasis holds pivotal
significance in clinical practice. The identification
of thrombotic risk factors, prognostication of
disease severity based on coagulation profiles,
and delineating optimal anticoagulation strategies
are pressing concerns in managing COVID-19-
associated coagulopathy.This paper aims to
comprehensively dissect the intricate relationship
between COVID-19 and blood coagulation,
shedding light on the underlying mechanisms
driving coagulopathy and the consequential
implications for hemostasis. By synthesizing
current knowledge, it endeavors to provide
insights into the pathophysiological intricacies
and guide strategies for optimized clinical
management in this evolving landscape of
COVID-19-associated coagulation abnormalities.
COVID-19 and Coagulopathy
The coronavirus disease 2019 (COVID-19)
caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has been associated
with a spectrum of clinical manifestations,
including coagulopathy that significantly impacts
disease severity and patient outcomes. COVID-
19-associated coagulopathy has garnered
substantial attention due to its complex and
multifaceted nature, leading to thrombotic
complications and contributing to morbidity and
mortality in affected individuals [12-16].COVID-
19 is known to induce endothelial injury, leading
to endotheliitis and disruption of the endothelial
barrier. This endothelial dysfunction contributes
to a prothrombotic state, promoting microvascular
thrombosis and contributing to systemic organ
damage [17-19].Severe COVID-19 cases are
characterized by a dysregulated immune response
and cytokine storm, resulting in systemic
inflammation. The cytokine release, particularly
interleukin-6 (IL-6), activates coagulation
pathways, leading to a hypercoagulable state and
an increased risk of thrombosis [20-22].SARS-
CoV-2 infection can trigger platelet activation,
causing an increase in platelet-monocyte
aggregates and platelet hyperreactivity. This
heightened platelet activation contributes to the
formation of microthrombi and disseminated
intravascular coagulation (DIC) in severe cases
[23].COVID-19-induced coagulopathy involves
perturbations in the coagulation cascade,
including elevated levels of D-dimers, fibrinogen,
and von Willebrand factor. Concurrently, there
might be a decrease in anticoagulant factors,
contributing to a prothrombotic state [24-
25].Patients with severe COVID-19 exhibit an

Int. J. Curr. Res. Med. Sci. (2023). 9(11): 16-22
18
increased incidence of venous thromboembolism
(VTE), pulmonary embolism (PE), stroke, and
myocardial infarction. These thrombotic events
are associated with adverse outcomes,
necessitating vigilant monitoring and prompt
intervention.Moreover, ongoing research
endeavors are focused on elucidating predictive
biomarkers, refining treatment protocols, and
investigating the long-term consequences of
COVID-19-induced coagulopathy to optimize
management strategies and enhance patient
care.The complex interplay between COVID-19
and coagulopathy underscores the need for
comprehensive approaches to address the
hemostatic alterations associated with this viral
illness. Continued research efforts aimed at
deciphering the underlying mechanisms and
identifying effective therapeutic interventions are
crucial in mitigating the thrombotic complications
and reducing the disease burden imposed by
COVID-19-associated coagulopathy.
Hemostasis Implications
The implications of COVID-19 on hemostasis are
profound and multifaceted, encompassing
alterations in various components of the
coagulation system, platelet function, endothelial
integrity, and fibrinolytic pathways. The
dysregulation of hemostasis mechanisms in
COVID-19 contributes significantly to disease
severity, thrombotic complications, and adverse
clinical outcomes [26].COVID-19 is associated
with changes in clotting factors, including
elevated levels of fibrinogen, von Willebrand
factor, and factor VIII. These alterations
contribute to a hypercoagulable state and promote
thrombus formation, predisposing patients to
venous and arterial thrombotic events.SARS-
CoV-2 infection triggers platelet activation and
aggregation, leading to increased platelet-
monocyte aggregates and platelet hyperreactivity.
The enhanced platelet activation contributes to
microvascular thrombosis and systemic
inflammation, exacerbating the coagulopathy
observed in severe cases.COVID-19-induced
endotheliitis and endothelial injury compromise
endothelial function, resulting in impaired
antithrombotic properties and a prothrombotic
state. This endothelial dysfunction contributes to
microvascular thrombosis and vascular
complications seen in severe COVID-19
patients.COVID-19 is associated with impaired
fibrinolysis, leading to reduced clot breakdown
and fibrin accumulation. Altered fibrinolytic
pathways contribute to the formation of fibrin-
rich microthrombi, contributing to organ damage
and thrombotic events.The hemostatic alterations
in COVID-19 patients culminate in an increased
risk of thrombotic complications, including deep
vein thrombosis (DVT), pulmonary embolism
(PE), stroke, myocardial infarction, and systemic
thromboembolic events. These complications
significantly impact patient morbidity and
mortality.The implications of COVID-19 on
hemostasis underscore the critical need for
vigilant monitoring of coagulation parameters,
risk stratification for thrombotic events, and
tailored therapeutic interventions. Anticoagulation
strategies, including prophylactic and therapeutic
anticoagulation, are being explored to mitigate
thrombotic risks in severely ill COVID-19
patients.
Clinical Implications and Management
The clinical implications of COVID-19-induced
coagulopathy are far-reaching, necessitating a
comprehensive approach to manage thrombotic
risks, mitigate complications, and improve patient
outcomes. Addressing these implications involves
vigilant monitoring, risk stratification, and
implementing appropriate management strategies
tailored to the individual patient's needs
[27].Routine monitoring of coagulation
parameters, including D-dimers, fibrinogen, and
platelet counts, assists in assessing thrombotic
risk and disease severity in COVID-19 patients.
Elevated D-dimer levels, in particular, serve as
prognostic markers for severe disease and
increased thrombotic propensity.Implementing
thromboprophylaxis protocols, including
pharmacological agents such as low molecular
weight heparin (LMWH) or unfractionated
heparin (UFH), in hospitalized COVID-19
patients based on individual risk stratification and
clinical severity. Prophylactic anticoagulation
aims to prevent venous thromboembolism (VTE)
in high-risk individuals without increasing
bleeding complications.In severely ill COVID-19

Int. J. Curr. Res. Med. Sci. (2023). 9(11): 16-22
19
patients with confirmed thrombotic complications
or markedly elevated D-dimer levels, therapeutic
anticoagulation might be warranted. However, the
decision to initiate therapeutic anticoagulation
should consider the individual's bleeding risk and
clinical status.Tailoring treatment strategies based
on a patient's clinical condition, comorbidities,
and coagulation profile is pivotal. Individualized
approaches aim to balance the thrombotic risks
and bleeding complications in COVID-19
patients.Regular monitoring of coagulation
parameters and clinical status is essential in
assessing the response to anticoagulation therapy,
identifying complications, and adjusting treatment
regimens accordingly. Long-term follow-up to
manage thrombotic risks post-discharge is also
crucial.Considering thrombotic complications in
specific scenarios, such as COVID-19 patients in
critical care settings, pregnant women, and
pediatric patients, to tailor appropriate
management strategies addressing the unique
needs of these populations.Ongoing research
endeavors focus on refining treatment protocols,
investigating optimal anticoagulation strategies,
evaluating novel therapies, and identifying
predictive biomarkers to enhance risk
stratification and guide management
decisions.Collaboration among healthcare
professionals, including hematologists,
pulmonologists, intensivists, and thrombosis
experts, facilitates optimal patient management
and decision-making in addressing COVID-19-
associated coagulopathy.Strategies for managing
COVID-19-associated coagulopathy remain an
active area of research and clinical exploration.
The dynamic nature of this viral illness mandates
continual reassessment of treatment protocols and
integration of emerging evidence to refine
management strategies, ultimately aiming to
reduce thrombotic risks and improve outcomes
for affected individuals.
Future Directions
Understanding the complexities of COVID-19-
associated coagulopathy remains a crucial area of
exploration, and future directions in research and
clinical practice aim to address key aspects to
enhance patient care and outcomes.Continued
research efforts focus on identifying reliable
predictive biomarkers that can stratify thrombotic
risk and predict disease severity in COVID-19
patients. Identification of specific markers
indicative of hypercoagulability or susceptibility
to thrombotic events could aid in risk assessment
and guide therapeutic interventions.Further
refinement and optimization of anticoagulation
protocols, including dosage, duration, and
selection of anticoagulants, are essential.
Tailoring anticoagulation regimens based on
individual patient characteristics, disease severity,
and coagulation profiles to balance thrombotic
risks and bleeding complications are areas of
ongoing research.Investigation of novel
therapeutic interventions targeting specific
components of the coagulation cascade or
addressing endothelial dysfunction in COVID-19
patients. This includes exploring potential agents
that modulate platelet function, mitigate
endothelial injury, or modulate the inflammatory
response to improve hemostasis and reduce
thrombotic risks.Longitudinal studies focusing on
the long-term consequences of COVID-19-
associated coagulopathy are necessary to
understand the persistence of thrombotic risks
beyond the acute phase of illness. Strategies for
post-discharge thromboprophylaxis and
management to reduce long-term thrombotic
complications need further investigation.Rigorous
clinical trials evaluating various anticoagulation
strategies, therapeutic agents, and risk mitigation
approaches in COVID-19 patients are pivotal to
establish evidence-based guidelines and refine
best practices in managing coagulopathy
associated with this viral illness.Development and
validation of comprehensive risk stratification
models integrating clinical, laboratory, and
imaging data to predict thrombotic events, guide
therapeutic decisions, and improve patient
outcomes.Continued collaboration among
researchers, clinicians, and experts across
disciplines to share insights, data, and
experiences, facilitating a comprehensive
understanding of COVID-19-associated
coagulopathy and enabling the translation of
research findings into clinical practice.Continued
research endeavors, clinical collaborations, and
advancements in understanding the
pathophysiology of COVID-19-associated
coagulopathy are pivotal in refining management

Int. J. Curr. Res. Med. Sci. (2023). 9(11): 16-22
20
strategies, optimizing patient care, and mitigating
thrombotic risks in affected individuals.
Conclusion
The intricacies of COVID-19-associated
coagulopathy have unveiled a critical intersection
between viral infection and hemostasis,
presenting a multifaceted challenge in clinical
management. The evolving understanding of the
interplay between COVID-19 and coagulation
disturbances underscores the imperative need for
continued research, vigilant monitoring, and
refined management strategies to improve patient
outcomes. Advancing our understanding of the
pathophysiological mechanisms, refining
therapeutic approaches, and integrating
multidisciplinary efforts are pivotal in addressing
the hemostatic implications of COVID-19. By
embracing these future directions, healthcare
providers can optimize management strategies,
enhance patient care, and mitigate the impact of
coagulopathy in the context of this global health
crisis.
References
1. Stawicki SP, Jeanmonod R, Miller AC,
Paladino L, Gaieski DF, Yaffee AQ, De
Wulf A, Grover J, Papadimos TJ, Bloem C,
Galwankar SC. The 2019–2020 novel
coronavirus (severe acute respiratory
syndrome coronavirus 2) pandemic: A joint
american college of academic international
medicine-world academic council of
emergency medicine multidisciplinary
COVID-19 working group consensus paper.
Journal of global infectious diseases.
2020;12(2):47.
2. Ogar CO, Okoroiwu HU, Obeagu EI, Etura
JE, Abunimye DA. Assessment of blood
supply and usage pre-and during COVID-19
pandemic: a lesson from non-voluntary
donation. Transfusion Clinique et
Biologique. 2021;28(1):68-72.
3. Obeagu EI, Babar Q. Covid-19 and Sickle
Cell Anemia: Susceptibility and Severity. J.
Clinical and Laboratory Research.
2021;3(5):2768-0487.
links/617acdd03c987366c3f8b3f1/Covid-19-and-
Sickle-Cell-Anemia-Susceptibility-and-
Severity.pdf.
4. Obeagu EI. COVID 19: Factors Associated
with Implementation and Practice of Covid-
19 Prevention. Int. J. Adv. Multidiscip. Res.
2022;9(9): 37-42.DOI:
10.22192/ijamr.2022.09.09.004
5. Nnodim J, Njoku-Obi T, Ohalete C, Obeagu
EI. Perspective of Covid 19 Hesistancy.
Madonna University journal of Medicine
and Health Sciences. 2022;2(1):235-8.
https://madonnauniversity.edu.ng/journals/in
dex.php/medicine/article/view/50.
6. Obeagu EI, Babar Q, Vincent CC, Anyanwu
CO. INFANTS IMMUNIZATION:
CHALLENGES OF OTHER VACCINES
DUE TO COVID-19 PANDEMIC. Journal
of Bioinnovation. 2021;10(4):1056-
66.links/6105aef21e95fe241a9e607a/INFA
NTS-IMMUNIZATION-CHALLENGES-
OF-OTHER-VACCINES-DUE-TO-
COVID-19-PANDEMIC.pdf.
7. Obeagu EI, Scott GY, Amekpor F, Ofodile
AC, Chukwueze CM. A Systematic Review
on the role of untreated inflammation of the
genital tract in SARS COV 2 transmission.
Madonna University journal of Medicine
and Health Sciences. 2023;3(1):19-
24.https://www.journal.madonnauniversity.e
du.ng/index.php/medicine/article/view/98.
8. Obeagu EI, Hamisi S, Bunu UO. An update
on cytokine storm in covid-19 infection:
Pivotal to the survival of the patients. Int. J.
Adv. Res. Biol. Sci. 2023;10(3): 171-
80.DOI: 10.22192/ijarbs.2023.10.03.020
9. Obeagu EI. Mental Health Care during the
COVID-19 Pandemic. Journal of Public
Health and Nutrition.
2020;3(5).links/6012dc1792851c2d4dfebad
6/Mental-Health-Care-during-the-COVID-
19-Pandemic.pdf.
10. Asogwa EI, Obeagu EI, Abonyi OS, Elom
CO, Udeoji DU, Egbumike CJ, Agunwah
EU, Eze CN, Akamike IC, Esimai BN.
Mitigating the Psychological Impacts of
COVID-19 in Southern Nigeria; Public
Awareness of Routine Exercises and
Preventive Measures. Journal of

Int. J. Curr. Res. Med. Sci. (2023). 9(11): 16-22
21
Pharmaceutical Research International.
2021;33(30A):72-83.
11. Obeagu EI, Babar Q, Vincent CC, Okafor
CJ, Eze R, Chijioke UO, Ibekwe AM,
Uduchi IO. Pulmonary Embolism in Covid-
19 Pandemic: A Threat to Recovery of the
Infected Patients. Journal of Pharmaceutical
Research International. 2021;33(42A):90-8.
12. Kolodziej LM, van Lelyveld SF, Haverkort
ME, Mariman R, Sluiter-Post JG, Badoux P,
de Koff EM, Koole JC, Miellet WR, Swart
AN, Coipan EC. High Severe Acute
Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) Household Transmission
Rates Detected by Dense Saliva Sampling.
Clinical Infectious Diseases. 2022;75(1):
e10-9.
13. Obeagu EI, Babar Q, Uduchi IO, Ibekwe
AM, Chijioke UO, Okafor CJ, Vincent CC.
An Update on Transfusion Related
Immunomodulation (TRIM) in a Time of
COVID-19 Pandemic. Journal of
Pharmaceutical Research International.
2021;33(42A):135-46.
14. Okorie N, Adeniran OC, Adimabua OP,
Obeagu EI, Anastasia E. Pathological
Changes among Norvegicus Rattus Exposed
on Novel Smoked Bambusa Vulgaris
(Bamboo) Leaf: Cigarette Substitute during
COVID-19 Lockdown in Nigeria. Journal of
Advances in Medical and Pharmaceutical
Sciences. 2022;24(7):30-9.
15. Nakyeyune S, Ikpenwa JN, Madekwe CC,
Madekwe CC, Tolulope AA, Ajayi DT,
Obeagu EI, Hassan AO. COVID 19
Omicron: The Origin, Presentation,
Diagnosis, Prevention and Control. Asian
Journal of Research in Infectious Diseases.
2022:25-33.
16. Etido A, Obeagu EI, Okafor CJ, Chijioke
UO, Vincent CC, Mojo-Eyes GC. The
Dynamics of Innate and Adaptive Immune
Response to Sars Cov-2 Infection and Its
Limitations in Human Beings. Journal of
Pharmaceutical Research International.
2021;33(45A):10-25.
17. Xu SW, Ilyas I, Weng JP. Endothelial
dysfunction in COVID-19: an overview of
evidence, biomarkers, mechanisms and
potential therapies. Acta Pharmacologica
Sinica. 2023;44(4):695-709.
18. Obeagu EI, Obeagu GU, Chukwueze CM,
Ngwoke AO. Inappropriate use of personal
protective equipment among health workers:
A review of associated factors. Int. J. Curr.
Res. Chem. Pharm. Sci. 2023;10(8): 27-
34.DOI: 10.22192/ijcrcps.2023.10.08.004
19. Obeagu EI, Nwosu DC, Obeagu GU.
Interleukin-6 (IL-6): A Major target for
quick recovery of COVID-19 patients. Int.
J. Curr. Res. Biol. Med. (2022). 7(2): 1-19.
DOI: 10.22192/ijcrbm.2022.07.02.001
20. Mohamed Khosroshahi L, Rezaei N.
Dysregulation of the immune response in
coronavirus disease 2019. Cell Biology
International. 2021;45(4):702-7.
21. Ifeanyi OE, Mercy OH, Prayer NN,
Chijindu OH. Cytokines, coagulation profile
and haematological changes in covid 19
patients as indicators of their health staus: A
review. European Journal of Biomedical.
2020;7(7):724-
9.links/5f083f4e299bf188161034aa/CYTO
KINES-COAGULATION-PROFILE-AND-
HAEMATOLOGICAL-CHANGES-IN-
COVID-19-PATIENTS-AS-INDICATORS-
OF-THEIR-HEALTH-STATUS-A-
REVIEW.pdf.
22. Obeagu EI, Scott GY, Amekpor F, Ugwu
OP, Alum EU. Covid-19 Infection and
Diabetes: A Current Issue. International
Journal of Innovative and Applied Research.
2023;11(1):25-30.
23. Li T, Yang Y, Li Y, Wang Z, Ma F, Luo R,
Xu X, Zhou G, Wang J, Niu J, Lv G.
Platelets mediate inflammatory monocyte
activation by SARS-CoV-2 spike protein.
The Journal of Clinical Investigation.
2022;132(4).
24. Hassan AO, Obeagu EI, Ajayi DT, Tolulope
AA, Madekwe CC, Madekwe CC, Ikpenwa
JN, Nakyeyune S. COVID 19 Omicron: The
Origin, Presentation, Diagnosis. Prevention
and Control. Asian Journal of Research in
Infectious Diseases. 2022;11(1):25-33.
25. Ifeanyi OE. Emerging clinical & medical
challenges and appropriate solutions during
COVID-19 pandemic times. Med Clin Rev.
2020;6(5):108. DOI: 10.36648/2471-

Int. J. Curr. Res. Med. Sci. (2023). 9(11): 16-22
22
299X.6.5.108
links/6012db46299bf1b33e30a9ec/Emergin
g-Clinical-Medical-Challenges-and-
Appropriate-Solutions-during-Covid-19-
Pandemic-Times.pdf.
26. Sharma S, Tyagi T, Antoniak S. Platelet in
thrombo-inflammation: Unraveling new
therapeutic targets. Frontiers in
immunology. 2022; 13:1039843.
27. Korompoki E, Gavriatopoulou M, Hicklen
RS, Ntanasis-Stathopoulos I, Kastritis E,
Fotiou D, Stamatelopoulos K, Terpos E,
Kotanidou A, Hagberg CA, Dimopoulos
MA. Epidemiology and organ specific
sequelae of post-acute COVID19: a
narrative review. Journal of Infection.
2021;83(1):1-6.
Access this Article in Online
Website:
www.ijcrims.com
Subject:
Medical Sciences
Quick Response Code
How to cite this article:
Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu and Matthew Chibunna Igwe. (2023). COVID-19
and Blood Coagulation: Implications for Hemostasis. Int. J. Curr. Res. Med. Sci. 9(11): 16-22.
DOI: http://dx.doi.org/10.22192/ijcrms.2023.09.11.004